This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Non Small Cell Lung Cancer

THE FIRST DUAL IMMUNOTHERAPY IN 1L NSCLC

View indication details

  • OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Expert opinion

NEW

Pr Dooms on 9LA
update at 4 years

Presented at ASCO 2023

Where is the highest unmet
medical need in 1L mNSCLC?

BTOS 2023 BMS symposium
with Dr Deschepper

ECLIPSE webinar series for continuous I-O learning via live peer-to-peer clinical practice exchanges

Product information

A short video on
the rationale of combining
OPDIVO and YERVOY
in collaboration with
P. Coulie

Dosing scheme
OPDIVO+YERVOY
+ 2 CT cycles
in 1L NSCLC

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

Patient support program
OPDIVO + YERVOY

A diary for your patients treated with
OPDIVO + YERVOY

www.immunooncology.be

An educational website
on immunotherapy
for your nurses

For more patient & nurse materials
click here

1L NSCLC, first-line non small cell lung cancer; CT, chemotherapy; irAE(s), immune-related adverse events(s)